Are nanoparticles the key to more effective eye drops?

Article

Researchers at the University of Reading, UK, report that they have discovered a potential way of making eye drops more effective.

Researchers at the University of Reading, UK, report that they have discovered a potential way of making eye drops more effective.

The researchers report in Molecular Pharmaceutics that they have developed nanoparticles that could attach to the cornea and resist being washed out by tear fluid for an extended period of time. If these nanoparticles are loaded with a drug, the researchers say, their longer attachment to the cornea would ensure more medicine penetrates the eye and improves drop treatment.

Professor Vitaliy Khutoryanskiy, from the University of Reading's School of Pharmacy, said, "Treating eye disorders is a challenging task. Our corneas allow us to see and serve as a barrier that protects our eyes from microbial and chemical intervention. Unfortunately this barrier hinders the effectiveness of eye drops. Many medicines administered to the eye are inefficient, as they often cannot penetrate the cornea barrier. Only the very small molecules in eye drops can penetrate [a] healthy cornea.

"Our research in bovine models showed that penetration of small drug molecules could be improved by adding enhancers such as cyclodextrins," Prof. Khutoryanskiy added. "This means eye drops have the potential to be a more effective, and a more comfortable, future treatment for disorders such as age-related macular degeneration."

In the same paper, the researchers revealed insights into how the structure of the cornea prevents various small and large molecules, as well as nanoparticles, from entering into the eye, and examined the effects any damage to the eye would have in allowing these materials to enter the body.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.